JP2013517307A - 心臓病の処置 - Google Patents

心臓病の処置 Download PDF

Info

Publication number
JP2013517307A
JP2013517307A JP2012549249A JP2012549249A JP2013517307A JP 2013517307 A JP2013517307 A JP 2013517307A JP 2012549249 A JP2012549249 A JP 2012549249A JP 2012549249 A JP2012549249 A JP 2012549249A JP 2013517307 A JP2013517307 A JP 2013517307A
Authority
JP
Japan
Prior art keywords
ser
lys
arg
glu
asp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2012549249A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013517307A5 (enExample
Inventor
セベルウ ペテルセン イェルゲン
ルイーズ キョエルビー アンネ
スコウガード マリー
デュールンド ペデルセン ヘンリック
アクセルセン レネ
リベル ディッテ
マイアー エディ
シュルツ ハンセン リー
フォスゲラウ ケルド
デュー ラーセン ビャルネ
Original Assignee
ジーランド ファーマ アクティーゼルスカブ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43928934&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2013517307(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ジーランド ファーマ アクティーゼルスカブ filed Critical ジーランド ファーマ アクティーゼルスカブ
Publication of JP2013517307A publication Critical patent/JP2013517307A/ja
Publication of JP2013517307A5 publication Critical patent/JP2013517307A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
JP2012549249A 2010-01-20 2011-01-20 心臓病の処置 Withdrawn JP2013517307A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29665710P 2010-01-20 2010-01-20
US61/296,657 2010-01-20
PCT/DK2011/050018 WO2011088837A1 (en) 2010-01-20 2011-01-20 Treatment of cardiac conditions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016074097A Division JP6200025B2 (ja) 2010-01-20 2016-04-01 心臓病の処置

Publications (2)

Publication Number Publication Date
JP2013517307A true JP2013517307A (ja) 2013-05-16
JP2013517307A5 JP2013517307A5 (enExample) 2014-03-13

Family

ID=43928934

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012549249A Withdrawn JP2013517307A (ja) 2010-01-20 2011-01-20 心臓病の処置
JP2016074097A Active JP6200025B2 (ja) 2010-01-20 2016-04-01 心臓病の処置

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016074097A Active JP6200025B2 (ja) 2010-01-20 2016-04-01 心臓病の処置

Country Status (15)

Country Link
US (1) US20130157953A1 (enExample)
EP (1) EP2525809B1 (enExample)
JP (2) JP2013517307A (enExample)
KR (1) KR20120128129A (enExample)
CN (1) CN102892425A (enExample)
AU (1) AU2011206979B2 (enExample)
BR (1) BR112012018104A2 (enExample)
CA (1) CA2786934A1 (enExample)
CL (1) CL2012002037A1 (enExample)
EA (1) EA026384B1 (enExample)
IL (1) IL220876A0 (enExample)
MX (1) MX342409B (enExample)
NZ (1) NZ601167A (enExample)
PH (1) PH12012501494A1 (enExample)
WO (1) WO2011088837A1 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017503474A (ja) * 2013-11-06 2017-02-02 ジーランド ファーマ アクティーゼルスカブ グルカゴン−ｇｌｐ−１−ｇｉｐトリプルアゴニスト化合物
JP2017536343A (ja) * 2014-10-10 2017-12-07 ノヴォ ノルディスク アー／エス 安定したｇｌｐ−１ベースのｇｌｐ−１／グルカゴン受容体コアゴニスト
JP2019112437A (ja) * 2013-10-17 2019-07-11 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
JP2021506955A (ja) * 2017-12-21 2021-02-22 イーライ リリー アンド カンパニー インクレチン類似体およびその使用
JP2023525260A (ja) * 2020-05-09 2023-06-15 天津薬物研究院有限公司 二重受容体アゴニスト作用を有するポリペプチド誘導体及びその用途

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5635529B2 (ja) 2008-12-15 2014-12-03 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
JP5635531B2 (ja) 2008-12-15 2014-12-03 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
NZ593813A (en) 2008-12-15 2013-02-22 Zealand Pharma As Glucagon analogues
WO2010070252A1 (en) 2008-12-15 2010-06-24 Zealand Pharma A/S Glucagon analogues
ME02220B (me) 2009-07-13 2016-02-20 Zealand Pharma As Analozi acilovanog glukagona
SG184988A1 (en) 2010-04-27 2012-11-29 Zealand Pharma As Peptide conjugates of glp-1 receptor agonists and gastrin and their use
AR081975A1 (es) * 2010-06-23 2012-10-31 Zealand Pharma As Analogos de glucagon
EP2585482B1 (en) * 2010-06-24 2019-03-27 Zealand Pharma A/S Glucagon analogues
CA2853884A1 (en) 2011-11-03 2013-05-10 Zealand Pharma A/S Glp-1 receptor agonist peptide gastrin conjugates
SG11201403377QA (en) * 2011-12-23 2014-07-30 Zealand Pharma As Glucagon analogues
WO2013164483A1 (en) 2012-05-03 2013-11-07 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
MY170671A (en) 2012-07-23 2019-08-26 Zealand Pharma As Glucagon analogues
TWI608013B (zh) * 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
AR092873A1 (es) * 2012-09-26 2015-05-06 Cadila Healthcare Ltd Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
CA2891931A1 (en) * 2012-11-20 2014-05-30 Mederis Diabetes, Llc Improved peptide pharmaceuticals for insulin resistance
WO2014096179A1 (en) * 2012-12-19 2014-06-26 Novo Nordisk A/S Novel glp-1 receptor agonists with cholesterol efflux activity
SG10201705097PA (en) 2012-12-21 2017-07-28 Sanofi Sa Functionalized exendin-4 derivatives
PL2986313T3 (pl) 2013-04-18 2019-12-31 Novo Nordisk A/S Stabilni, dłużej działający współagoniści receptora glp-1/glukagonu do zastosowań medycznych
SI3057984T1 (sl) * 2013-10-17 2018-10-30 Zealand Pharma A/S Acilirani glukagonski analogi
US10093713B2 (en) * 2013-11-06 2018-10-09 Zealand Pharma A/S GIP-GLP-1 dual agonist compounds and methods
WO2015086729A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/gip receptor agonists
TW201609795A (zh) 2013-12-13 2016-03-16 賽諾菲公司 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
AR098616A1 (es) 2013-12-18 2016-06-01 Lilly Co Eli Péptido para el tratamiento de hipoglicemia severa
CN103724424B (zh) * 2013-12-27 2015-05-27 浙江省农业科学院 一种mPEG-SPA-pGLP-2复合物及其制备方法和应用
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
EP3151852A1 (en) 2014-06-04 2017-04-12 Novo Nordisk A/S Glp-1/glucagon receptor co-agonists for medical use
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
TWI705973B (zh) 2014-10-29 2020-10-01 丹麥商西蘭製藥公司 Ｇｉｐ促效劑化合物及方法
TN2017000271A1 (en) * 2014-12-30 2018-10-19 Hanmi Pharm Ind Co Ltd Glucagon derivative having improved stability
KR102418477B1 (ko) * 2014-12-30 2022-07-08 한미약품 주식회사 글루카곤 유도체
WO2016168388A2 (en) * 2015-04-14 2016-10-20 Palatin Technologies, Inc. Therapies for obesity, diabetes and related indications
TWI707867B (zh) 2015-04-16 2020-10-21 丹麥商西蘭製藥公司 醯化之昇糖素類似物
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TN2017000555A1 (en) 2015-06-30 2019-04-12 Hanmi Pharm Ind Co Ltd Glucagon derivative and a composition comprising a long acting conjugate of the same
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
PH12018501409B1 (en) 2015-12-31 2023-03-10 Hanmi Pharmaceutical Co Ltd Triple glucagon/glp-1/gip receptor agonist
EP3888667B1 (en) 2016-06-09 2023-10-25 AmideBio LLC Glucagon analog and methods of use thereof
JP7208020B2 (ja) 2016-06-29 2023-01-18 ハンミ ファーマシューティカル カンパニー リミテッド グルカゴン誘導体、その結合体、及びそれを含む組成物、並びにその治療的用途
WO2018104561A1 (en) 2016-12-09 2018-06-14 Zealand Pharma A/S Acylated glp-1/glp-2 dual agonists
CN116143939A (zh) * 2017-11-24 2023-05-23 浙江道尔生物科技有限公司 一种治疗代谢疾病的多重活性蛋白
CN120887972A (zh) * 2017-11-24 2025-11-04 浙江道尔生物科技有限公司 一种治疗代谢疾病的胰高血糖素类似物
CN111818971A (zh) 2018-01-03 2020-10-23 梅德瑞斯糖尿病有限责任公司 用于治疗nash和其他紊乱的改进的肽药物
WO2021083306A1 (zh) * 2019-10-31 2021-05-06 东莞市东阳光生物药研发有限公司 Glp-1/gcg双受体激动剂多肽
EP3842060A1 (en) * 2019-12-23 2021-06-30 Merck Sharp & Dohme Corp. Stapled lactam co-agonists of the glucagon and glp-1 receptors
CN117202924A (zh) 2020-12-07 2023-12-08 斯皮特弗尔制药有限责任公司 使用glp-1r和gcgr平衡激动剂降低血糖和/或体重的治疗方案和方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002509078A (ja) * 1998-02-13 2002-03-26 アミリン・ファーマシューティカルズ，インコーポレイテッド エキセンジンおよびｇｌｐ−１の変力および利尿効果
JP2004512311A (ja) * 2000-10-20 2004-04-22 アミリン・ファーマシューティカルズ，インコーポレイテッド Ｇｌｐ−１ペプチドによる冬眠心筋および糖尿病性心筋症の治療
WO2008101017A2 (en) * 2007-02-15 2008-08-21 Indiana Unversity Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
WO2008152403A1 (en) * 2007-06-15 2008-12-18 Zealand Pharma A/S Glucagon analogues
WO2009155258A2 (en) * 2008-06-17 2009-12-23 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6703359B1 (en) * 1998-02-13 2004-03-09 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and GLP-1
JP4394279B2 (ja) 1998-03-09 2010-01-06 ジーランド ファーマ アクティーゼルスカブ 酵素加水分解に対する傾向が減少した薬理学的に活性なペプチド複合体
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
US7192922B2 (en) * 2002-11-19 2007-03-20 Allegheny-Singer Research Institute Method of treating left ventricular dysfunction
WO2007100535A2 (en) 2006-02-22 2007-09-07 Merck & Co., Inc. Oxyntomodulin derivatives
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
JP5753779B2 (ja) 2008-06-17 2015-07-22 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ 生理学的ｐＨの緩衝液中で向上した溶解性及び安定性を示すグルカゴン類縁体
US20100240883A1 (en) * 2009-03-18 2010-09-23 Nian Wu Lipid-drug conjugates for drug delivery
TWI608013B (zh) * 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002509078A (ja) * 1998-02-13 2002-03-26 アミリン・ファーマシューティカルズ，インコーポレイテッド エキセンジンおよびｇｌｐ−１の変力および利尿効果
JP2004512311A (ja) * 2000-10-20 2004-04-22 アミリン・ファーマシューティカルズ，インコーポレイテッド Ｇｌｐ−１ペプチドによる冬眠心筋および糖尿病性心筋症の治療
WO2008101017A2 (en) * 2007-02-15 2008-08-21 Indiana Unversity Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
WO2008152403A1 (en) * 2007-06-15 2008-12-18 Zealand Pharma A/S Glucagon analogues
WO2009155258A2 (en) * 2008-06-17 2009-12-23 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6015002015; Ｃｉｒｃｕｌａｔｉｏｎ　Ｒｅｓｅａｒｃｈ Ｖｏｌ．ＸＸＶＩ, 1970, ｐ．２２５-２３３ *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019112437A (ja) * 2013-10-17 2019-07-11 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
JP2017503474A (ja) * 2013-11-06 2017-02-02 ジーランド ファーマ アクティーゼルスカブ グルカゴン−ｇｌｐ−１−ｇｉｐトリプルアゴニスト化合物
JP2017536343A (ja) * 2014-10-10 2017-12-07 ノヴォ ノルディスク アー／エス 安定したｇｌｐ−１ベースのｇｌｐ−１／グルカゴン受容体コアゴニスト
JP2021506955A (ja) * 2017-12-21 2021-02-22 イーライ リリー アンド カンパニー インクレチン類似体およびその使用
JP2022033724A (ja) * 2017-12-21 2022-03-02 イーライ リリー アンド カンパニー インクレチン類似体およびその使用
JP7658877B2 (ja) 2017-12-21 2025-04-08 イーライ リリー アンド カンパニー インクレチン類似体およびその使用
JP2023525260A (ja) * 2020-05-09 2023-06-15 天津薬物研究院有限公司 二重受容体アゴニスト作用を有するポリペプチド誘導体及びその用途

Also Published As

Publication number Publication date
KR20120128129A (ko) 2012-11-26
EA026384B1 (ru) 2017-04-28
NZ601167A (en) 2014-12-24
CA2786934A1 (en) 2011-07-28
MX342409B (es) 2016-09-28
WO2011088837A1 (en) 2011-07-28
EA201290540A1 (ru) 2013-03-29
MX2012008440A (es) 2012-08-15
JP2016138127A (ja) 2016-08-04
EP2525809B1 (en) 2016-08-03
IL220876A0 (en) 2012-09-24
JP6200025B2 (ja) 2017-09-20
AU2011206979B2 (en) 2015-09-10
CN102892425A (zh) 2013-01-23
AU2011206979A1 (en) 2012-08-02
CL2012002037A1 (es) 2012-09-07
BR112012018104A2 (pt) 2017-10-17
PH12012501494A1 (en) 2012-10-22
US20130157953A1 (en) 2013-06-20
EP2525809A1 (en) 2012-11-28

Similar Documents

Publication Publication Date Title
JP6200025B2 (ja) 心臓病の処置
JP6849720B2 (ja) グルカゴン類似体
KR102505628B1 (ko) 글루카곤 및 glp-1 수용체의 장기-작용성 공-효능제
CN105745222B (zh) 酰化胰高血糖素类似物
JP6334537B2 (ja) グルカゴン類似体
JP5635530B2 (ja) グルカゴン類似体
JP5635529B2 (ja) グルカゴン類似体
US10766939B2 (en) Amylin analogues
US20110293587A1 (en) Glucagon analogues
TW201202265A (en) Glucagon analogues
KR20140114845A (ko) 글루카곤 유사체
CN103068841A (zh) 胰高血糖素类似物
JP2012532898A (ja) アシル化グルカゴン類似体
JP6006264B2 (ja) グルカゴン類似体
JP5912150B2 (ja) グルカゴン類似体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140120

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150127

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150424

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150727

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20151201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160401

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160404

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20160427

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20160519